SCHEMBL4479467

SCHEMBL4479467

CC(=O)Oc1c(C)cc(O)c(C(C)=O)c1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.54
KDM4E B2RXH2 2/20 0.54
HSD17B10 Q99714 2/20 0.54
TP53 P04637 1/20 0.54
GAA P10253 1/20 0.54
MAPT P10636 1/20 0.54
POLB P06746 3/20 0.44
CYP3A4 P08684 5/20 0.44
HPGD P15428 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
USP2 O75604 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALDH1A1 P00352 1/20 0.38
PREP P48147 3/20 0.37
CELA1 Q9UNI1 2/20 0.37
KDR P35968 1/20 0.37
ACHE P22303 2/20 0.36
KCNA3 P22001 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13738810 0.84 CYP3A4 (0.47) HTTKDM4EHSD17B10TP53GAA
SCHEMBL721909 0.83 HTT (0.59) HTTKDM4EHSD17B10TP53GAA
SCHEMBL4462555 0.83 KDM4E (0.51) HTTKDM4EHSD17B10TP53GAA
SCHEMBL4464395 0.81 CYP3A4 (0.40) HTTKDM4EHSD17B10TP53GAA
SCHEMBL4469962 0.80 CYP3A4 (0.39) HTTKDM4EHSD17B10TP53GAA
SCHEMBL10624847 0.78 KDM4E (0.52) HTTKDM4EHSD17B10TP53GAA
SCHEMBL7554717 0.76 HTT (0.56) HTTKDM4EHSD17B10TP53GAA
SCHEMBL8377612 0.76 HTT (0.54) HTTKDM4EHSD17B10TP53GAA
SCHEMBL13735982 0.75 CYP3A4 (0.52) HTTKDM4EMAPTPOLBCYP3A4
SCHEMBL10941837 0.75 KDM4E (0.49) HTTKDM4EHSD17B10TP53GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
EP-1836183-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS Galileo Pharmaceuticals, Inc. (US) 2007-09-26 EP disclosed
WO-2006065686-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS GALILEO PHARMACEUTICALS, INC. (US) 2006-06-22 WO disclosed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors ALOX15B, ALOX5, ALOX15 HTT 3071/4885KDM4E 3310/4885HSD17B10 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.